Hepatitis C New Zealand

June 11, 2012

Hepatitis C New Zealand treatment numbers from 2009 – 2011

Hepatitis C New Zealand treatment numbers from 2009 – 2011

This information is a reply to a official information act request for these figures from NZ ministry of Health May 2012

Interesting to note the significant decline in numbers treated for Hepatitis C  over this period

2009  =  721

2010  =  578

2011  =  478

 

New Zealand Hepatitis C treatment figures, which include the number of patients in each district health board (DHB) who have completed treatment for hepatitis C with Pegylated Interferon and Ribavirin during 2011 and the preceding years  as follows..

 

 

2009 2010 2011
Auckland 131 43 36
Bay of Plenty 36 32 27
Canterbury 90 81 45
Capital and Coast 41 40 21
Counties Manukau 56 34 37
Hawkes Bay 15 8 11
Hutt Valley 14 19 20
Lakes 19 19 19
Mid Central 20 28 19
Nelson Marlborough 27 24 28
Northland 28 25 17
Otago 32 44 48
South Canterbury 9 6 6
Southland 12 17 6
Tairawhiti 1 2 7
Taranaki 16 25 22
Waikato 24 31 13
Wairarapa 9 2 7
Waitemata 75 58 43
West Coast 10 13 10
Whanganui 25 16 23
Unknown 31 11 13
721 578 478

 

I thought decline in numbers treated  might have something to do with drug trials but apparently these figures include those on drug trials  that use Pegylated Interferon and Ribavirin

“In answer to your question, PHARMAC determine the funding of a product in the community and the restrictions (if any) that apply to it. In the case of pegylated interferon with or without ribavirin we fund these products for patients who meet the Special Authority criteria. There is nothing in our Special Authority criteria that would prohibit a patient undergoing a clinical trial receiving a funded therapy. We do not actively fund therapy in pharmaceutical trials, therefore anyone who is receiving funded therapy met our funding criteria as well as the entry criteria for the trial. ”

Greg Williams  | Senior Therapeutic Group Manager Pharmac

 

And in case your wondering where unknown is , that likely means the patient  ( a NZ citizen ) was treated in another country where they are resident.

 

best of health

www.hcv.org.nz

“A community of people with hepatitis C trying to help other people who are affected by hepatitis C”

September 17, 2011

Hepatitis C New Zealand


Deportation threat for hepatitis caught from prostitutes

Mr Veng, a postgraduate accountancy student, had been given the medical clearance for a student visa in 2006 but his application for a further visa in 2009 was declined after the department found him to have an unacceptable standard of health.

http://www.nzherald.co.nz/nz/news/article.cfm?c_id=1&objectid=10738304

Rotorua mayor supporting World Hepatitis Day

Know it, confront it’ is the theme for World Hepatitis Day 2011 and Mayor Kevin Winters is getting behind the initiative by declaring Thursday 28 July World Hepatitis Day in Rotorua.

http://www.voxy.co.nz/health/rotorua-mayor-supporting-world-hepatitis-day/5/95727

Hepatitis: The Silent Killer

Monday, 25 July 2011, 2:24 pm
Press Release: Hepatitis Foundation

“We need to dramatically increase the number of New Zealanders who receive antiviral treatment for their disease to mitigate this health and financial burden.

http://www.scoop.co.nz/stories/GE1107/S00115/hepatitis-the-silent-killer.htm

Many with Hep C not diagnosed or treated

Nelson health practitioners say a large chunk of people may not have been diagnosed with or treated for the “silent epidemic” of hepatitis C.

http://www.stuff.co.nz/nelson-mail/news/5336062/Many-with-Hep-C-not-diagnosed-or-treated

Wairarapa wars on hepatitis

Needle exchange manager Brendon Olsen said hepatitis B and C was common among intravenous drug users but the exchange had helped lower infections.

“[Hepatitis B + C] is prevalent but it has dropped.

http://www.times-age.co.nz/news/wairarapa-wars-on-hepatitis/1063989/

Hepatitis war can be won – expert

Hepatitis can be “obliterated in a generation” if intravenous drug users stick to clean needles and hepatitis B vaccinations reach almost 100 per cent of the population, a MidCentral Health gastroenterologist says.

“The tragic thing is it could in fact be eradicated quite quickly,” Dr Andrew Herbert said.

Hepatitis can be “obliterated in a generation” if intravenous drug users stick to clean needles and hepatitis B vaccinations reach almost 100 per cent of the population, a MidCentral Health gastroenterologist says.

“The tragic thing is it could in fact be eradicated quite quickly,” Dr Andrew Herbert said.

Hepatitis can be “obliterated in a generation” if intravenous drug users stick to clean needles and hepatitis B vaccinations reach almost 100 per cent of the population, a MidCentral Health gastroenterologist says.

“The tragic thing is it could in fact be eradicated quite quickly,” Dr Andrew Herbert said.

http://www.stuff.co.nz/manawatu-standard/news/5352845/Hepatitis-war-can-be-won-expert

HEP C TV advert from Christchurch

Watch out for hepatitis C when its raining blood


http://youtu.be/ognSdeTF97M

 

Hepatitis Foundation of New Zealand Parliamentary Breakfast

World Hepatitis Day; Hon Tariana Turia, Associate Minister of Health

Spreading the message that you can protect yourself against hepatitis B by getting immunised. Being prepared to share strategies around preventing hepatitis by taking precautions – practising safe sex, using sterile injecting equipment – and not sharing razors, toothbrushes or drug-taking equipment.

And if there’s anything to get us going – it’s the knowledge that in New Zealand, less than a quarter of those infected with hepatitis C know they have it.

All of us here today, have a clear mission to change the status of this disease from being a silent killer to a condition that can be treated and managed. It can be as simple as one, two, three.

http://www.voxy.co.nz/health/speech-world-hepatitis-day-turia/5/97728

Outpatients clinic in jail treats hep C prisoners

Four prisoners are currently being treated for hepatitis C through the outpatients clinic the Whanganui District Health Board established at Whanganui Prison in February.

They are among 15 Wanganui people being treated for the disease by the outpatients department.

http://www.wanganuichronicle.co.nz/news/outpatients-clinic-in-jail-treats-prisoners-with-h/1105721/

best of health www.hcv.org.nz

 

 

 

April 14, 2011

Hepatitis C New Zealand Blog April

Christchurch Hepatitis C resource Centre post quake

Quake destroyed premises, but Centre rises again thanks to dedicated staff like Fleur who now operates Christchurch Hepatitis C resource centre out or her home until they find temporary premises

Fleur here (Office Admin/Education Coordinator) We have only just set up the
work computer here at my home until we find temporary premises.

So emails will now get through. Our work phone number has been diverted to
my home number also -so from 9-4pm there will be someone to answer the call.
The (0800 224 372) helpline number is being answered by Otago Hepatitis
Resource Centre until we get our premises sorted.

Contact details for
Hepatitis C Resource Centre Christchurch

Phone 03 366 3608, Fax 03 366 0649
0800 224372 (0800 22 HEPC)
hcv@xtra.co.nz

New Fibro scan machine for Christchurch

Some good news for Christchurch, with a new fibro scan machine being installed in the city. These machines remove the need for a liver biopsy. Scanning the liver with sound waves.

They are very cost effective at around $200 for a fibro scan versus the more expensive approx $1200 for a liver biopsy, we hope more DHB’s will invest in fibro scan machines

Liver biopsy has been a significant deterrent to undergoing treatment for Hepatitis C the introduction of fibro scan machines is a great step forward for patients

At present there are machines in Auckland Waikato and now Christchurch.

Contract to develop services for Improvements in Hepatitis C Services

Hepatitis Foundation Recently awarded a national Ministry of Health contract to develop services for Improvements in Hepatitis C Services. I recent meeting with them left me feeling positive about the future of Hepatitis C in New Zealand and we will watch with interest the progress on developing improved services for those living with Hepatitis C.

Hepatitis Foundation mission statement

To promote positive health outcomes to the people of New Zealand through education and research into viral hepatitis, and early detection and long-term follow-up of chronic hepatitis B and C.

The aims of the new Hepatitis C project

Establishing the current status of Hepatitis C (HCV) service delivery and will include assessing the differing status, issues, service delivery models and needs for individuals with HCV within DHBs and regions. The findings will contribute to strategies and / or recommendations for the implementation of key interventions.

Shared Care Tool. Shared care between primary care and specialist services for these groups of patients will manage and, if possible, avert any downstream complications.

Fibro scanning. Equitable access to fibro scanning technology will allow all patients with HCV to have access to this technology in order to assess the stage of liver damage. Assessment of liver damage is usually required before patient treatment plans are commenced.

The development of education / information resources for specific sub-population ‘risk’ groups. These resources will support better detection and treatment of infected individuals from these groups.

Research and provide an implementation plan for a potential three-year programme to promote the targeted testing of specific ‘at risk’ groups to improve early HCV diagnosis rates and treatment options for these individuals. Development of a plan for targeted testing will enable implementation of more effective detection and treatment of at-risk groups.

Undertake research and development of innovative HCV service delivery model(s) for New Zealand. Time-limited pilot projects with appropriate evaluation will improve future access to and quality of HCV treatment services.

An assessment of the current status of HCV Service delivery in New Zealand. Establishing the current status of Hepatitis C (HCV) service delivery will act as a primary tool for the accurate assessment and design of new interventions, and will include: assessing the differing status, issues, service delivery models and needs for individuals with HCV within DHBs and regions. The findings will contribute to strategies and / or recommendations for the implementation of key interventions.

Hepatitis Foundation Hepatitis C Project Team

Kelly Barclay (Hepatitis C Project Manager)

Phone: 021 636 931

Email: kelly@hepfoundation.org.nz

Helen Payne (Hepatitis C project coordinator)

Phone: 021 621 416

Email: helen@hepfoundation.org.nz

The Ministry has launched an e-learning tool for Hepatitis C for  general practitioners and nurses.

http://learnonline.health.nz/course/view.php?id=41

Some general information for Hepatitis C patients

http://learnonline.health.nz/file.php/41/Resources/Hep%20C%20Resources%20-%20Patient%20Information.pdf

Auckland resource Centre

Auckland resource Centre has undergone another regime change and emerged stronger check out their latest publication full of informative goodness about Hepatitis C here, One of the best newsletter to come out of NZ that I have seen look forward to more for the new team who you can read all about inside.

Auckland Hepatits C Liverlinks magazine

New hepatitis C  inhibitor drugs to market in Europe and USA

Perhaps the biggest new this month is the progress of the new hepatitis C inhibitor drugs to market in Europe and USA.

An FDA advisory panel will review both Merck’s boceprevir and Vertex’s telaprevir on successive days next month. (April 2011) I expect both will get positive recommendations from the committees considering the unmet need, high efficacy — cure rates in the 70% range — and reasonable safety record.

The drugs haven’t been tested head-to-head against each other, but based on their individual trials, Vertex and marketing partner Johnson & Johnson (NYSE: JNJ ) seem to have the upper hand.


While both drugs work better than current treatments and are even able to cure patients that failed previous treatments, they still require PegIntron or Pegasys to be taken alongside the oral medications. The treatment time can be shortened from 48 weeks down to 24 weeks, but that still means patients are injecting themselves and dealing with nasty side effects for six months.

http://www.fool.com/investing/high-grow … at-up.aspx

Expensive new hepatitis c Drugs

They are going to be expensive but bring a dramatic improvement in treatment outcomes.

New hepatitis C drugs from Merck & Co. and Johnson & Johnson (JNJ) are being sold in France for 22,000 euros ($31,271) and more, a precedent some doctors say may limit access after the medicines are approved throughout Europe.

J&J and Vertex Pharmaceuticals Inc. (VRTX)’s telaprevir costs 22,000 euros under a French program for seriously ill patients for whom there is no other effective treatment on the market, according to patient association SOS Hepatites. Merck & Co. said its boceprevir costs 30,000 euros under the same program.

The price may drop once the drugs are approved for the broader market, Merck and J&J executives said. Still, the French model shows the new drugs may triple the cost of hepatitis C treatment, leaving England, Russia and eastern Europe likely to delay use or restrict which patients are allowed access, said Antonio Craxi, director of gastroenterology and internal medicine at the University of Palermo.

“It may be that we can’t use it at all until the price comes down,” Mark Thursz, professor of hepatology at Imperial College London, said in an interview at a conference in Berlin over the weekend. “It’s not the best economic environment to launch an expensive new drug.”

The U.K.’s National Institute for Health and Clinical Excellence may restrict the new drugs to patients who have tried existing treatments without success, Thursz said. The agency may also require genetic tests to determine whether patients are likely to respond to the medicines, he said at the meeting of the European Association for the Study of the Liver.

Best of Health

www.hcv.org.nz

February 28, 2011

Comparison figures for Hepatitis C patient treatment numbers in New Zealand 2007 2010

Here are the comparison figures for Hepatitis C patient treatment numbers in New Zealand 2007 2010.

Patients treated for Hepatitis C in New Zealand
2010 2007
Auckland 45 88
Bay of plenty 44 10
Canterbury 93 73
Capital and coast 43 35
Counties Manuka 38 17
Hawkes Bay 11 12
Hutt Valley 20 15
Lakes 19 13
mid central 28 8
Nelson / Marlborough 26 11
Northland 29 15
Otago 47 17
South Canterbury 7
Southland 15 7
Tairawhiti 2
Taranaki 25 3
Waikato 35 24
Wairarapa 3 0
Waitemata 55 35
West Coast 16 11
Whanganui 16 14
616 408

* The 2007 figures come from New Zealand Ministry of Health Stock take of Existing Services May 2007 May 2008

* The Christchurch (2007) figures come from a official information request to Canterbury DHB

* The 2010 figures come from a reply to a official information act  request from Hon Tony Ryall NZ Minister of Health Feb 2010

(note the 2010 figures received were for 11 months I have added a estimated monthly figure for December 2010 to bring figures up to a year for comparison purposes).

Numbers treated for Hepatitis C in New Zealand overall increased during the period 2007 – 2010

Numbers treated for Hepatitis C in New Zealand overall increased from 408 in 2007 to 616 in 2010.

One reason for the increase may be the 2009  Pharmac funding of treatment for genotype 2 & 3 patients who according to Prof Ed Gane make up 40 to 45 per cent of NZ hep c patients. Previously these patients were not eligible for funded treatment and were under treated in some DHB regions, such as Otago.

There is a noticeable increase in numbers treated in some regions.

And a decline in some regions such as Auckland.

If you’re a hepatitis C patient access to treatment has improved especially if you have genotype 2 or 3 , or live in one of the regions with substantial  improvement in treatment numbers,  such as Taranaki  from 3 patients in 2007 to 23 in 2010

best of health

www.hcv.org.nz

January 19, 2011

January Hepatitis C New Zealand blog

January 2011 Hepatitis C New Zealand blog

This blog dedicated to memory of Bethli Wainwright

Bethli an Auckland woman whose liver transplant prompted her to set up a website for other liver patients has died.

Bethli Wainwright, 44, died in Auckland Hospital on Christmas Day 2010

Wainwright created a website for liver patients as she waited for her own liver transplant several years ago.

She said then she wanted to provide the information she was looking for as she waited for a transplant.

She also wanted the opportunity to make her donor family proud of the decision they had made “in giving me the gift of life”.

Wainwright also researched issues surrounding liver transplants, including her research paper entitled “Liver transplantation as a catalyst for change”. It covered the social and economic wellbeing outcomes for New Zealand patients who were given a new liver between 1998 and 2005.

http://tvnz.co.nz/health-news/battler-l … es-3989744

http://www.livers.org.nz/

beach

New Zealand Ministry of health still confused about counting Hepatitis C numbers

I was reading the Hepatitis C information page on New Zealand Ministry of heath web site.
http://www.moh.govt.nz/moh.nsf/indexmh/hepatitis-q&a
“How many people have hepatitis C ?

Worldwide about 200 million people have been infected with hepatitis C. More than 33,000 of them are New Zealanders. There are thought to be at least 25 new infections in New Zealand each week.”
Ministry of Health fantasy land : 25 new infections a week according to ministry of health?

Reality : But what does the ministry of health’s own public health surveillance actually say about the actual rate of infection ?
20 cases for the whole year  November 2009 – 2010

The Institute of Environmental Science and Research Ltd (ESR) is under contract with the Ministry of Health (MoH) contributes to the national public health surveillance effort. Including Hepatitis C
http://www.surv.esr.cri.nz/
http://surv.esr.cri.nz/PDF_surveillance/MthSurvRpt/2010/201011NovDHBRolling.pdf

So New Zealand Ministry of health claim 1300 new case of hepatitis c per year but can only account for 20 new cases of hepatitis C per year.

Gee wonder which figure the NZ ministry of health use for planning? 20 the actual number of diagnosed new hepatitis C cases per year or the or the  fantasy figure of 1300 new infections per year ?

The ministry needs to get real about accurately measuring hepatitis C. There is a huge gap between 1300 new cases per year and the 20 recorded cases.

In Australia there has been a recent push to establish needle exchanges in prisons

Fight looms on jail needle plan

BY BIANCA HALL
05 Jan, 2011 01:00 AM
The ACT Government is on a collision course with territory jail staff after indicating the nation’s first prison needle-exchange program could be introduced at the Alexander Maconochie Centre.

ACT Health Minister Katy Gallagher said yesterday that a new draft report of an 18-month audit of drug use in the AMC made a strong health case for a needle and syringe program within prison walls.

ACT Health figures show more than half of male inmates tested in June were hepatitis C positive. About two-thirds of women tested screened positive for the virus’s antibodies.
http://www.canberratimes.com.au/news/local/news/general/fight-looms-on-jail-needle-plan/2039520.aspx

Injecting hope into our prisons

ASSOCIATE PROFESSOR LYNNE MAGOR-BLATCH

A 2010 study found 33.6per cent of NSW male prisoners continued to inject while in prison, and at 90per cent, the rate of needle sharing was far higher than within the general community. This makes prisons incubators of disease.

Switzerland was the first country to provide a prison-based NSP in 1992. Since then, programs have been established in more than 50 prisons in 12 countries. This doesn’t mean that authorities have become lax on drug supply reduction.

In fact, results of these programs have not found an increase in injecting or other drug use.

They have, however, found decreased rates of blood-borne viruses, reduced needle sharing and even a decrease in needle stick injuries.

There is no evidence that a controlled NSP within the prison would threaten correctional staff safety. Rather, there is evidence that safety will be increased with a significant reduction in risky behaviours and a safer prisoner return on release to families and the community.

In April 2010, the Australian Health Ministers Advisory Council released three related hepatitis C and HIV strategies. In relation to prison-based NSPs, all three noted the appropriateness for governments ”to identify opportunities for trialling the intervention in Australian custodial settings”.
http://www.canberratimes.com.au/news/opinion/editorial/general/injecting-hope-into-our-prisons/2041494.aspx?storypage=0

Experts bolster calls for jail needle exchange

Anex chief executive John Ryan says until authorities can eliminate drugs from prisons, they have a duty of care to minimise the spread of blood-borne diseases.

“The international evidence and the evidence from around Australia is prisons are high risk environments, for particularly hepatitis C transmissions, we can’t rule out an outbreak of HIV transmission,” he said.

“People are injecting often after at least five others have used the needle, so we’re talking about extremely hazardous injecting practices.”

Mr Ryan says such a program would save the community a lot of money.

“For every dollar invested, you get four saved in the health budget. If you look at other issues, like loss of productivity, for every dollar invested you get a $27 return,” he said.

“The savings are massive and obviously we need to be making those sorts of savings in the prison system.”
http://www.abc.net.au/news/stories/2011/01/14/3112618.htm

Will be interesting to see if needle exchanges are ever established in prisons in NZ ?

Looks like Teleprivar in likely to be approved for use mid 2011

Shasun Chem to launch ‘Hepatitis C’ in June-July 2012

The supply of the Hepatitis C drug to Vertex by Shasun Chemicals is set to take off earlier than anticipated. The product is set to launch in June-July next year. “Commercial supplies have already started and we are preparing for the launch this year,” says Vimal Kumar, Managing Director of Shasun Chemicals, in an exclusive interview with CNBC-TV18’s

Q: The markets expecting that your supplies of Hepatitis C to Vertex will begin very soon. By when can you assure your investors that those supplies will kick off?

A: I cannot give details. But yes, one of the products is in Phase III, the regulatory approvals are expected to be in place by April-May and the launch to set to happen somewhere in June-July next year. Commercial supplies have already started and this year, we are preparing for the launch.

Q: Can you give us a sense of how much things could get preponed, considering the developments that have already occurred?

A: Commercial supplies have already started. Our UK subsidiary Shasun Pharma Solutions should do a topline of about 39 million pounds which is up from 32 million pound. Overall sales would grow by almost 25% over in the UK.

Q: Just with specific reference to the deal with Vertex, the estimates are that the revenues could stand to generate USD 50 to 60 million and that could actually go all the way up to USD 1 billion plus. Is that your target as well?
http://www.moneycontrol.com/news/business/shasun-chem-to-launch-hepatitis-cjune-july-2012_510464.html

Top 10 Hepatitis C News Stories of 2010 according to m Alan Franciscus from http://www.hcvadvocate.org
http://www.hcvadvocate.org/presentations/Top%20Ten%202010.htm

Best of Health for 2011-01-19
www.hcv.org.nz

October 4, 2010

October 2010 NewZealand Hepatitis C Blog

Hepatitis C the  Nine Billion Dollar target market and  the race for new drug treatments

Hepatitis C is one of the most lucrative new markets for drugs in the world.

Motivated by the huge profits Drug companies are pouring resources in to discovering the next big treatment

For Hepatitis C, the standard has been  a combination of interferon and ribavirin.

In simple terms, ribavirin is an antiviral medication that stops the virus that causes hepatitis C from spreading. Interferon prevents viral replication in surrounding cells.

Now a score of companies are racing to bring new treatments on stream. Out front are Merck (NYSE:MRK – News) with boceprevir, and a partnership of Vertex Pharmaceuticals (NMS:VRTX) and Johnson & Johnson (NYSE:JNJ – News) with telaprevir.

Both drugs are protease inhibitors, which prevent a virus from replicating itself. While they treat the same disease, they are different in both results and side effects.

Used on patients who have had no previous treatment, boceprevir and telaprevir beat down the hepatitis C virus to undetectable levels in 66% and 75% of patients respectively

By most counts, the global market for hepatitis C products is now $4 billion a year. According to a report from the commercial analysis firm Research & Markets, that should rise to $8.5 billion by 2016.

http://finance.yahoo.com/news/The-Race- … l?x=0&.v=1

These new drugs are taken with existing drugs in a combination of three drugs sometimes known as triple therapy

Details of Open hepatitis C drug trials in New Zealand

Some of these drug trials for drugs like telaprevir have been and are being conducted in New Zealand.
http://clinicaltrials.gov/ct2/results?term=hepatitis+c+New+zealand&recr=Open

Although the drugs are expected to get FDA approval next year in America (the most lucrative and largest market for these drugs) they may take several years more to reach New Zealand and be approved / funded by Pharmac.

They will add another pharmaceutical cost to treatment

If you have Hepatitis C genotype one it does improve your odds of successful treatment and maybe a shorter term of treatment.

Come out of the warehouse now ?

BURLINGTON, Mass., Sept. 27 /PRNewswire/ — Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that the launch of novel therapies for the treatment of Hepatitis C Virus (HCV), including Vertex/Johnson & Johnson/Mitsubishi Tanabe’s telaprevir and Merck’s boceprevir, will precipitate several changes in HCV treatment. According to Patient Flow in Hepatitis C Virus, surveyed physicians plan to initiate treatment in at least half of their “warehoused” HCV1 patients one year after novel therapies become available. Patient “warehousing” is a term that has been coined to characterize the phenomenon of HCV patients opting out of treatment with current standard of care in anticipation of new therapies; psychiatric events, adverse events and liver health are top reasons keeping patients away from current therapies.

The report also finds that time from initial diagnosis to treatment initiation will decrease once novel HCV therapies are available. On average, surveyed physicians stated they wait 17 months to initiate treatment in HCV1 treatment-naive patients; this time will decrease to 7 months once novel treatment options are available.

“The arrival of telaprevir and boceprevir will alter more than the drug-treatment rate and treatment initiation timing in HCV,” said Alexandra Makarova, M.D., Ph.D. “Physicians indicate they would increase the capacity of their HCV practice to accommodate the additional patients expected once novel therapies are available.”

http://www.prnewswire.com/news-releases/launch-of-novel-agents-for-the-treatment-of-hepatitis-c-virus-will-precipitate-treatment-of-at-least-half-of-warehoused-patients-103849343.html

clutha

Drug survey  RECENT TRENDS IN ILLEGAL DRUG USE IN NEW ZEALAND, 2006-2009

Findings from the 2006, 2007, 2008 and 2009 Illicit Drug Monitoring System
(IDMS)

Scary reading with the growing methamphetamine use, As people inject  methamphetamine much more frequently injecting themselves forty or fifty time a day to maintain the high  amphetamine psychosis, irrational impulsive behaviour a bad combination for transmission of hepatitis C and other BBV. Many of these new methamphetamine idu people will be new to using intravenous drugs and naive in their safety precautions.

http://www.shore.ac.nz/projects/Final%202009%20IDMS%20report.pdf

Surveillance of HIV and Hepatitis C Prevalence among Attendees of Needle Exchanges throughout New Zealand Chantal Lauzon

Well an interesting read with lots of detail a thesis submitted for the degree of Masters of Public Health at the University of Otago, Dunedin, New Zealand  another resource for those interested in Hepatitis C and needle exchanges.

“Results
In total, data from 480 respondents were included in the analysis. The majority of
respondents were male (67.3%), of European ethnicity (79.4%) and aged between
35 and 49 years. Average duration of injecting drugs was 17 years. Overall, the
seroprevalence of HIV in this population has remained very low (<1%) and there
has been a significant decline (17.6%) in the seroprevalence of HCV between 2004
and 2009 (p<0.0001). Prevalence of HCV-antibody was associated with older age,
longer duration of injecting, and a history of imprisonment, methadone treatment
and tattooing. There has been a significant increase (20%; p<0.001) in the reported
use of new needles and syringes for every injection.
Conclusions
The decline in HCV seroprevalence in injecting drug users cannot be attributed to
any particular differences in demographic characteristics of survey participants or
to trends in risk behaviours associated with risk of HCV transmission. The
national introduction of the free one-for-one needle and syringe exchange
programme in 2004 has had a large impact on growth in distribution at needle
exchanges. This reduction in economic barriers to safe injection and subsequent
increased access to sterile needles and syringes appears to have had a positive
impact on injecting practice and is possibly a factor behind the decline in HCV
seroprevalence among New Zealand IDUs who use the needle exchange
programme. The 2009 Needle Exchange Blood Borne Virus Serosurvey
contributes to the evidence base supporting the effectiveness of needle exchange
programmes in reducing injecting risk and limiting the spread of HIV and HCV
among IDUs. “

http://ourarchive.otago.ac.nz/bitstream/handle/10523/388/LauzonHCVSeroprevalenceInNZIDUs.pdf?sequence=1

The importance of narrative video

The english Hepatitis C Trust need new case studies to raise awareness in the press. We are always writing new reports, releasing new statistics and





Well that’s it

Best of Health

www.hcv.org.nz

http://www.facebook.com/pages/Hepatitis-C-New-Zealand/99254558387

July 23, 2010

100% Pure New Zealand Hepatitis C

100% Pure New Zealand Hepatitis C

Who do I have to tell if I have Hepatitis C In New Zealand?

Hepatitis C and Disclosure

Someone asked about Hepatitis C and disclosure

With some help from the Hepatitis C resources Centre Dunedin and the New Zealand

Ministry of Health the definitive reply seems to be.

DISCLOSURE
A person with hepatitis C is not legally required to disclose his/her positive

status unless he/she is,
*A member of, or applying to join, the New Zealand defense force.
*A healthcare worker undertaking exposure-prone procedures.
*Donating blood.

Page 19 of the little yellow book of Hep C Facts,:

If you would like a copy of   the little yellow book of Hep C Facts ring

Hepatitis C Helpline New Zealand 0800 224372 (0800 22 HEPC) or email  the Otago

Hepatitis C Resource Centre hepcotago @xtra.co.nz

Hep C Concert Christchurch

Thank you to Roger Grauwmeijer Rokpx.com Roger@RokPx.com for the images from the day May 22 concert in thepark

chch11

chch82

Dunedin opened it’s new Hepatitis C resource centre

photos were taken speeches were made.

hepcopen2

An article about the opening and the centre’s worker Heath Te Au appeared in the

Otago Daily Times,

” Fresh chance inspires hepatitis C educator

Having a ruptured appendix in the 1990s may have helped save Heath Te Au’s life.

Blood tests taken at the time of this medical emergency showed that he had hepatitis C, most likely the result of sharing needles and drug equipment during a time when he was an intravenous drug user.

After his appendix removal a doctor asked him to think about what he was doing to himself.

Mr Te Au (40) said it was a wake-up call, something which led him to change his life.

He underwent treatment in 1999 and 2000 and is now clear of the blood-borne virus which had been caught early enough not to cause major liver damage.

Now, he uses his experience to help educate others in his role as manager and one of two educators at Otago’s Hepatitis C Resource Centre. ”

Where are the Hepatitis C Resources for Wellington ?

A very large proportion of the population have no access to hepatitis C resources

its’ dysfunctional and emphasis the New Zealand’s Ministry of Health’s complete

failure to address the needs of those affected and infected by the Hepatitis C

epidemic.

The New Zealand Ministry of health attempts to contact the victims of Croydon Day Clinic

Hep C tracking hampered by privacy issues

Health authorities have tested more than half the women in New Zealand potentially exposed to the hepatitis C virus in a Melbourne abortion clinic, but are being hampered by confidentiality rules which mean they cannot leave phone messages.

Fifty-six New Zealand women have called the Ministry of Health’s Healthline, concerned they had contracted the virus after James Latham Paters, an anaesthetist at Melbourne’s Croydon Day Surgery Clinic was now being investigated by police and medical authorities. More than 20 of his patients tested positive to a strain of hepatitis C identical to his own.

“The Australian Victorian health authorities have contacted 33 New Zealanders and the bulk of those have been tested,” said the ministry’s director of public health, Fran McGrath.

The New Zealand test result figures would be released as part of the Australian report once the contacting and testing process was completed. The ministry expected to have a further update in September.

Dr McGrath said contacting the women was a slow process because confidentiality requirements meant callers could not leave messages and had to repeatedly ring back.

“Even contacting one individual can take several calls followed by a registered letter, all of which can take a considerable period of time.”

http://www.stuff.co.nz/national/health/3918567/Hep-C-tracking-hampered-by-privacy-issues

Hepatitis C Resource Centre Otago Stakeholders Meeting June 16

Hep C Seminar Dunedin

Insights offered on hepatitis C, services

“Recent concern about the risk of hepatitis C to women who may have been treated at a private medical clinic in Melbourne highlights the need for increased awareness about the illness, clinical nurse specialist Margaret Fraser says.

Ms Fraser, who is the chairwoman of the reference group for Otago’s Hepatitis C Resource Centre, said there was still widespread ignorance about the condition.

http://www.odt.co.nz/news/dunedin/110725/insights-offered-hepatitis-c-services

After sorting out my family commitments I arrived late at 9.20 so missed the

Opening / powhiri ,  Heath Te Au , Hepatitis C Resource Centre Otago who works as

a phlebotomist and the needle exchange and Margaret Fraser the hepatitis c nurse

from Dunedin Hospital speaking about  Epidemiology and treatment of Hepatitis C

apologies that I missed them speaking.

Dr Janet Downs from the free doctor’s clinic at DIVO the Dunedin needle exchange

talked about  Hepatitis C in the community. She spoke eloquently about her work

at the needle exchange, if you live in Dunedin / Otago and want to see her at the

needle exchange free clinic for IDU Intravenous Drug Users ring the needle

exchange and make an appointment

Dr Michael Schultz, Hepatitis C and what happens if you decide against treatment

was the next speaker.

Key points  “everybody should be treated the earlier the better”

The younger you are when you begin treatment the better chance of a successful

outcome

There were some unique and disturbing aspects to the policy ?  of the Southern

District Heath Board

1, people are not able to get a second course of treatment if the first course

fails to successfully clear the hepatitis c virus.   One strike and you’re out

this just seems to be harsh when retreatment is an option in other DHB’s.

2, You have to have a biopsy in the Southern region ( Dr Schultz couldn’t

understand why anyone would complain about a biopsy as they obviously didn’t have

a problem with needles?)

A professional contact sent us this, “I contacted leading  NZ specialist expert

to clarify who needs a biopsy and who doesn’t.   Here is the response: “We have

never needed a biopsy for Gt 1 or HIV infected or haemophilia.  Only change is

for Gt 2 and 3 where now Peg/RBV is available to all rather than just those with

severe fibrosis.”
In the past only G2/G3 who has severe fibrosis could access funding, therefore

for this to be determined, a liver biopsy was needed.  The new funding for

treatment now includes all G2/G3 hep C patients; hence a liver biopsy may not be

necessary.
Interesting sounds like you may not have to have a biopsy in other DHB’s.

If a liver biopsy is a barrier to accessing treatment for some people (I think it

is) we would be better to remove it in some cases ?

Merrilee Williams RN, Otago hepatitis C nurse spoke about treating Hepatitis C

next she was knowledgeable and gave a informative presentation.

Michelle MacDonald, Psychiatric Liaison spoke on treating people with Hepatitis

C
and the neuro psychiatric effects of treatment

Depression
Fatigue
Irritability
Insomnia and sleep disturbances

She explained that preexisting mental health issues can and need to be treated

before treatment

Once these conditions are being treated they do not preclude someone from

successfully undertaking treatment.

Bill Jang, Christchurch Hepatitis C Resource Centre Te Waipounamu arrived by

helicopter (well maybe not, but he made a very brief appearance and then left) ,

he made the interesting point that the recent international 1 in 12 hepatitis

campaign was  actually one in forty New Zealanders have hepatitis B or C.

He has begun educating rest homes on Hepatitis C care.

Shame the needle exchange DIVO wasn’t there to advocate for their clients but

again they to seem to be uninterested in their client’s access to care or issues

surrounding Hepatitis C. Not surprising when the local needle exchange is now

entirely governed  and run from Christchurch as a skeleton service.

Wonder how that works with the Ottawa charter on public health. Best just ignore

best practice for public health and instead have our poorly performing health

services controlled from Christchurch.

The good news is there has been an increase in the number of people being treated

in Otago from 24 to 40. I imagine this is the people with genotype three who are

finally getting treatment after Pharmac changed the funding for treatment for

their genotype finally making it accessible.

If we do the calculation that 1% of Otago population has hep c a figure of 1800

people and the Otago/ Southern ? District Heath board treat 40 per year, we can

calculate that in just 45 years everyone would be diagnosed and treated.

Maybe Bill Jang is right about rest homes, assuming the undiagnosed infected live

that long.

It was a good opportunity to see Hepatitis C discussed in the community in such a

positive way a great morning well done to the organisers.

Their were lots of info  / pamphlets available and I picked up a glossy A4 brochure from Roche aimed at raising awareness amongst NZ General Practice Doctors which has to be a good thing.

You and Pegasys Together we can cure hepatitis C Identify and refer patients today.

gptogethercover

Roche pamphlet targeting GP’s.

With 75 % of hepatitis C patients undiagnosed it seems a timely resource

Each New Zealand GP practice on average would have 15 patients.  Most undiagnosed

and untreated.

txtrochegp

North Island Hepatitis C Resource Centre (Te Ika a Maui)

I just found this website for the North Island Hepatitis c Resouce Centre I’m

guessing it’s the replacement for the old site that seems to have disappeared the

Hepatitis C Resource Centre (Te Ika a Maui)   http://www.hepcresources.org.nz/

put on your sunglasses it’s bright with all those virus floating round.

pegypen

Best of Health

www.hcv.org.nz

June 2, 2010

New Zealand Hepatitis C Croydon Day Surgery

NZ Ministry of Health Press Release

2 June 2010

55 Women at Risk of Hep C being Traced

New Zealand and Australian health authorities are tracing 55 New Zealand women who visited a private medical clinic in Australia between 1 January 2006 and 7 December 2009 who may be at risk of having contracted Hepatitis C.

Ministry of Health Deputy Director of Public Health Dr Fran McGrath says Australian authorities identified the link between a cluster of hepatitis C cases and a private medical centre in the State of Victoria, Australia in April and are now investigating how this happened.

There is a police investigation in Victoria and media reports of legal action in Australia being planned.

“The Department of Health in Victoria, has taken responsibility for tracing, directly contacting and confidentially informing all 3,500 women concerned, including the 55 affected women giving a New Zealand address.”

The Department began contacting the New Zealanders yesterday as they worked through the 3500 women being traced. Around 1000 Australian women have been contacted and 746 tested.

Of those tested 44 have been found to have hepatitis C, around half of whom have had their infection linked to the private medical centre.

Because of the difficulties involved in tracing the women, the Ministry of Health will be working more closely with its Victorian counterpart in helping trace the New Zealand women concerned.

New Zealand women who had procedures at the Croydon Day Surgery in Croydon, Victoria from 1 January 2006 to 7 December 2009 can call Healthline in New Zealand and be transferred free of charge to a confidential Australian hepatitis line for further information.

“This is a sensitive and potentially distressing situation and the Ministry of Health here and health authorities in Australia are being careful to protect the privacy and confidentiality of the women involved”, Dr McGrath says.

Specialist staff in District Health Boards in New Zealand are on standby to offer blood testing, follow-up, support and treatment if necessary.

“Based on the results of women tested to date approximately 5% of women treated at the clinic may have contracted Hepatitis C. Based on this information we estimate that up to 3 New Zealand women may test positive.”

Any woman who has received treatment in a Melbourne private clinic in the four years from 2006 to 2009 should contact (New Zealand ) Healthline 0800 611 116 for advice.

Hepatitis C is a blood-borne virus that causes inflammation of the liver and which can have serious complications.

For more information contact Peter Abernethy, Media Relations Manager, 021 366 111

Further information can be found at the Victoria Department of Health website http://www.health.vic.gov.au/chiefhealthofficer/alerts/

Press release ends

Hepatitis C cases linked to doctor grows


AAP

The number of women infected with Hepatitis C after being treated by a Melbourne doctor has grown to 44 and is rising.

Another 32 women have tested positive to the infection after being treated by James Latham Peters, an anaesthetist at a Croydon abortion clinic, the Department of Human Services (DHS) revealed on Monday.

That number is certain to grow and the DHS has urged any women who have had abortions and been treated by Dr Peters at the Croydon Day Surgery to contact them.

The number of women infected with Hepatitis C after being treated by a Melbourne doctor has grown to 44 and is rising.

Another 32 women have tested positive to the infection after being treated by James Latham Peters, an anaesthetist at a Croydon abortion clinic, the Department of Human Services (DHS) revealed on Monday.

That number is certain to grow and the DHS has urged any women who have had abortions and been treated by Dr Peters at the Croydon Day Surgery to contact them.

More than 1100 women treated by Dr Peters since 2008 have been contacted by DHS and told to be tested, with the results of 746 women received showing 32 infection cases, Victoria’s chief health officer Dr John Carnie said.

Dr Carnie and police believe the doctor recklessly and maybe deliberately infected the women by using needles he had contaminated.

“The more cases you find in this instance, it becomes more and more difficult to explain this by any other accidental means,” Dr Carnie told reporters on Monday.

http://news.smh.com.au/breaking-news-national/hepatitis-c-cases-linked-to-doctor-grows-20100531-wpuu.html

best of health

www.hcv.org.nz

May 11, 2010

New Zealand World Hepatitis Day, May 19 2010

New Zealand World Hepatitis Day, May 19 2010  update

A couple of events for world Hepatitis month here in New Zealand

Hepatitis Free concert in Latimer Square Christchurch May 22 nd 11 am – 4 pm

The Hepatitis C Resource Centre Te Waipounamu in conjunction with World Hepatitis Day  proudly present a free concert in Latimer Square Christchurch Saturday May 22 nd 11 am – 4 pm info stalls, Sausage Sizzle,bouncy castle, byo picnic

Lots of Bands Squirm , Dialtones , Mynor Starr ,Anthesiac, Magic Eye, Anthesiac,Papanui High School Jazz combo, ChisnallwoodIntermediate Bands Vivid Distortion, Chain Reaction, Closing Time, 1.5l sprite bottle, DJ Detox Damage.

hepc-gigposter2010
further details contact Hepatitis C Resource Centre Christchurch phone 3663608  email hcv @xtra.co.nz

Opening of the new Hepatitis C Resource Otago Centre office May 19 2010

A great day out in Christchurch and if you make it to the event watch out for  Hepatitis C Resource Centre Dunedin phlebotimist Heath in his band,  Heath will be back in Dunedin on 19 May for the opening of the new Hepatitis C Resource Centre office in Dunedin.

further details contact Heath and  Allison at Otago  Hepatitis C Resource Centre hepcotago @xtra.co.nz

The past month has seen a lead up campaign of  one in twelve hepatitis  awareness ads played nationally on TV 3

best of health

www.hcv.org.nz

May 7, 2010

New Zealand Hepatitis C Blog May 2010

New Zealand Hepatitis C Blog May 2010

World Hepatitis Day, May 19, aims to raise global awareness of hepatitis B and hepatitis C and encourage prevention, diagnosis and treatment.
World Hepatitis Day is led by the World Hepatitis Alliance, which represents 200 patients groups and organizations
http://www.worldhepatitisday.org/en/Home.aspx

The Hepatitis Comics

Have a laugh with Lucinda K. Porter ‘s blog The Hepatitis Comics. Lucinda is hepatitis C positive and positively believes in the power of humour.

http://hepatitiscomics.blogspot.com/

Medical transmission of Hepatitis C from Australia

VICTORIANS worried about their contact with Dr James Latham Peters over the past four years should contact health authorities – not just patients of the doctor in 2008 and 2009, as first stated last week.

A spokesman for the Department of Health last night confirmed that Dr Peters had worked at Croydon Day Surgery – the clinic where he allegedly infected 12 patients with his own strain of hepatitis C – since 2006.

On Friday, Victoria’s chief health officer, Dr John Carnie, said the infected patients had visited the clinic between June 2008 and December last year, and that patients worried about their contact with him at the Croydon clinic during this period should contact the department.

He said departmental workers were also trying to contact patients they believed to be at risk of contracting the blood-borne virus from him during this 18-month period.

But the department spokesman last night said authorities would also encourage patients who visited Dr Peters at Croydon Day Surgery as far back as 2006 to seek further information from the department if they were worried about the virus.

As of last night, the department had received 830 calls from people with questions about the anaesthetist, who is believed to have been using drugs when he infected patients with his particular strain of the illness.

Last week, Dr Carnie said he referred the matter to police in March because he found it hard to imagine how the transmission of the virus had been accidental.

http://www.theage.com.au/victoria/officials-welcome-hepatitis-c-feedback-20100412-s4dx.html

Being Warehoused

‘Warehoused : when patients elect to wait for the new drugs’
Warehoused : Thought this was interesting about waiting for new treatments, I think you might have to wait extra long for pharmac to fund a new treatment in New Zealand. So maybe prepare to be in your warehouse with hep c for a long time ?

Hepatitis C Patients May Boost Merck, J&J, Vertex

http://www.businessweek.com

By Michelle Fay Cortez and Naomi Kresge

April 19 (Bloomberg) — At Fred Poordad’s bustling hepatitis C clinic in the heart of Los Angeles, one in every five patients receives no treatment. They are waiting for a wave of new drugs, expected in the next 18 months, that may boost their chance at a cure by as much as 10-fold.

They’re just the first among new therapies anticipated in the next five years as companies seek a single pill to cure the infection. Poordad, chief of hepatology at the Liver Disease and Transplant Center at Cedars-Sinai Medical Center in Los Angeles, doesn’t object when his patients elect to wait for the new drugs, a practice known as “warehousing.”

“The warehousing has been going on for the past year or so,” Poordad said. “I think we’ll see a tremendous increase in the volume of patients that are treated. That’s the most exciting thing in the field for a long time.”

The drugs closest to market, Merck’s boceprevir and telaprevir from Vertex and Johnson & Johnson, are protease inhibitors crafted from the technologies that led to discoveries made in the fight against HIV. The new treatments are being tested as additions to current standard treatments. Both drugs work by blocking the action of the protease enzyme the hepatitis virus needs to replicate, directly stopping it from spreading.

Warehoused better than a wallet biopsy………….

Telaprevir, has had a trial here in NZ recently, with another trial coming soon.

Adding the investigational drug telaprevir to standard treatment for hepatitis C infection cures about half the patients willing to give therapy a second try. That compares to a cure rate of just 14 percent among those who were re-treated with the standard regimen, according to researchers at Duke Clinical Research Institute.

http://www.youtube.com/watch?v=qwKJQgkdJ2s&feature=player_embedded

Happy Hepatitis month

best of Health

www.hcv.org.nz

Older Posts »

Powered by WordPress